GROUPE-ADP
Groupe ADP is launching the global challenge "Play Your Airport ". This open innovation initiative will allow students, businesses, travellers and the group's employees to reinvent the airport experience with one common goal: creating the airport of the future.
"The diversity of communities coming together around this bold initiative makes it the first of its kind in the airport industry. It is a powerful means to scour the globe to unearth new high-potential projects capable of revolutionising the current airport model. This venture will serve to identify external and internal talents, and staff members who submit winning entries will be eligible to receive intrapreneurial guidance," said Edward Arkwright, Deputy CEO of Groupe ADP.
"Play Your Airport " was developed in partnership with Agorize, which specializes in open innovation challenges; it is the concrete representation of Groupe ADP's commitment to innovation and collective intelligence. The Innovation Hub programme is the crystallization of the new direction Groupe ADP has taken within the framework of its strategic plan "Connect 2020". This programme embodies Groupe ADP's commitment to openness, transformation and competition by focusing on three complementary pillars: OPEN, CONNECT and INVEST.
"We can't wait to see the contributions that will support our studies on the developing Paris airports, in particular Paris-Charles de Gaulle Airport terminal 4 and active projects throughout our worldwide network of airports," said Edward Arkwright.
Each community will be guided by themes that Groupe ADP has identified: the city within the airport, the passenger experience, smart terminals and the "zero environmental impact" airport.
Conditions for participating in the contest can be found at the following website: www.play-your-airport.com . Challenge submissions will undergo a rigorous, multi-phase selection process. Juries will be composed of internal experts and qualified external figures. Challenge winners will be announced in January 2018.
The prize will be tailored to each individual community: The winning student team and travellers will receive plane tickets for a trip around the world. Businesses will receive up to €40,000 in funding and support for a project in the experimentation phase. Employees will receive a study trip to the innovation capital of the world—Silicon Valley.
More on the Innovation Hub programme pillars
OPEN : focused on propagating a culture of innovation and establishing an ecosystem of partners (incubators, academics, competition hubs, think tanks, etc.)
CONNECT : dedicated to sourcing, training and experimentation with innovative start-ups and SMEs
INVEST : created to take minority stakes in companies in order to establish strategic partnerships through ADP INVEST, the €16 million internal fund. ADP Invest provided funding for Pacifa Decisions, Egidium Technologies and, more recently, Safety Line—a French company that analyses data for the aviation and aeronautics sectors. Groupe ADP also serves as underwriter for three complementary external funds: X-Ange Capital 2 (SIPAREX), Cathay Innovation and Ellaia Delta.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170614005902/en/
Contact:
Groupe ADP
Elise Hermant, +33 1 74 25 23 23
Medias and
Reputation Department Manager
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom